CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• CD95/Fas stimulation is implicated in driving and maintaining cancer stem cells (CSCs).
• The precise molecular mechanisms linking CD95 signaling to cancer stemness remain incompletely understood.

Purpose of the Study:

• To elucidate the role of signal transducer and activator of transcription 1 (STAT1) in CD95-mediated cancer stemness.
• To identify the upstream signaling pathways and downstream targets involved in this process.

Main Methods:

• Investigated STAT1 activation and its downstream gene induction in response to CD95 stimulation in various cancer models.
• Utilized gene knockdown and knockout strategies to assess the necessity of STAT1 for CD95-induced stemness.
• Analyzed the role of type I interferons (IFNs) in mediating CD95-induced STAT1 activation and stemness.

Main Results:

• STAT1 is enriched in CSCs across different cancer types and is activated by CD95 stimulation.
• CD95 stimulation induces type I IFNs, which activate Janus-activated kinases (JAKs) and subsequently STAT1.
• STAT1 activation leads to the induction of genes associated with therapy resistance and promotes cancer stemness.
• STAT1 knockdown or knockout significantly abrogates the ability of CD95L or type I IFN to enhance cancer stemness.

Conclusions:

• STAT1 is a critical mediator of CD95-induced cancer stemness.
• Type I IFNs act as key signaling molecules in the CD95-STAT1 axis that drives cancer stemness.
• Targeting the STAT1 pathway may offer a therapeutic strategy to overcome therapy resistance driven by CSCs.